This could be an evidence that RUNX2 instead of RUNX1 could be involved in the manifestation of ETP-ALL that allows in vivo functional evaluation of putative oncogenes and preclinical drug testing. Here, RUNX1 is linked to acute lymphoblastic leukemia.